Paul S. Dunn, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 |
Aaron M Mendel, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 |
Celeste E. Straight, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 Fax: 508-545-2777 |
Dr. Gabrielle M Reine, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 |
David A Klein, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 555 Main St, Shrewsbury, MA 01545 Phone: 508-842-2010 Fax: 508-842-8790 |
Jane A. Molinari, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 |
Thomas F Halpin, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 Fax: 508-845-2777 |
Asmaa R. Al-kadhi, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 Fax: 508-845-2777 |
Hiral R. Warner, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 |
Maria Narducci, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 26 Julio Dr, Shrewsbury, MA 01545 Phone: 508-845-2323 |
Dr. Bernard Dale Magee, MD Obstetrics & Gynecology - Gynecology Medicare: Not Enrolled in Medicare Practice Location: 555 Main St, Shrewsbury, MA 01545 Phone: 508-842-2010 |
News Archive
For female Veterans with fibromyalgia (FM) symptoms, the impact of believing in their ability to begin and sustain a long-term exercise program appears to positively influence their results.
The Race to Yes campaign today lauded drug maker Sarepta on its plans to move forward immediately to seek FDA approval of the first drug to successfully treat Duchenne muscular dystrophy, the world's leading genetic killer of children.
Approximately one percent of all newborns in Switzerland are diagnosed with a congenital heart defect, roughly half of them require open heart surgery. Most children, including those with the most severe heart defects, survive because of the significant advancements in surgical techniques. Therefore, the current research focuses less on survival than on long-term consequences and quality of life of these children.
Laboratory Corporation of America® Holdings today announced the successful completion of its acquisition of Genzyme Genetics, a business unit of Genzyme Corp., in an all cash transaction valued at $925 million. Net of expected income tax benefits, less acquisition-related expenses, the acquisition has a net cash cost to LabCorp of approximately $795 million.
› Verified 4 days ago